Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 12/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 11/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 9/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.56 |
| ▸ | FDPS | P14324 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | ADK | P55263 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8310366 | 0.85 | ADRA2A (0.48) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL21556926 | 0.82 | — | — | |
| SCHEMBL2981194 | 0.82 | — | — | |
| SCHEMBL21067687 | 0.82 | ADRA2A (0.63) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL20457775 | 0.80 | — | — | |
| SCHEMBL14380959 | 0.80 | — | — | |
| SCHEMBL84663 | 0.80 | — | — | |
| Bromide SCHEMBL7211375 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL17162764 | 0.80 | — | — | |
| Iodide SCHEMBL11682763 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4649084-A1 | NITROGENOUS HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES | Merck Patent GmbH (DE) | 2025-11-19 | — | — | EP | disclosed |
| EP-4612157-A2 | NITROGENOUS HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES | Merck Patent GmbH (DE) | 2025-09-10 | — | — | EP | disclosed |
| CN-120152954-A | Nitrogen-containing heterocyclic compound for organic electroluminescent device | 默克专利有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2024149694-A1 | NITROGENOUS HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024094592-A2 | NITROGENOUS HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2024-05-10 | — | — | WO | disclosed |
| US-10077336-B2 | Functionalized highly branched melamine-polyamine polymers | BASF SE (DE) | 2018-09-18 | — | — | US | disclosed |
| EP-2545123-B1 | POLYAMIDES RESISTANT TO HOT AGEING | BASF SE (DE) | 2018-05-16 | — | — | EP | disclosed |
| EP-2610248-B1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | TEIJIN PHARMA LTD (JP) | 2016-06-08 | — | — | EP | disclosed |
| EP-2143727-B1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8916714-B2 | Method for producing phenyl-substituted heterocyclic derivative by means of coupling method using palladium compound | TEIJIN PHARMA LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1590442-A3 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-03 | — | — | EP | disclosed |
| EP-1590442-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20040266668-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040180815-A1 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors | NAKAJIMA SUANNE (US) | 2004-09-16 | — | — | US | disclosed |
| WO-2004072243-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004012506-A2 | ANTIMICROBIAL COMPOUNDS | EXEGENICS, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003020969-A2 | METHOD FOR MARKING L-NUCLEIC ACIDS | NOXXON PHARMA AG (DE) | 2003-03-13 | — | — | WO | disclosed |
| EP-1288309-A1 | Methods for labeling L-nucleic acids | Noxxon Pharma AG (DE) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266668-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, CTSC | ADRA2A 4778/4885ADRA2C 4458/4885ADRA1D 4796/4885 |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | ADRA2A 4627/4885ADRA2C 3973/4885ADRA1D 4674/4885 |
| US-20040180815-A1 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | ADRA2A 4625/4885ADRA2C 3886/4885ADRA1D 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.